Valproate (Valproic Acid / Divalproex) Depletions: What Mood Stabilizer Medications Deplete

Valproate encompasses a family of related compounds — valproic acid, divalproex sodium, and sodium valproate — that share the same active moiety but differ in formulation and release characteristics. Prescribed for epilepsy, bipolar mania, and migraine prevention, the class accounts for approximately 15 million prescriptions annually in the United States. Valproate's therapeutic mechanism operates through multiple pathways simultaneously: it enhances GABA neurotransmission, blocks voltage-gated sodium channels, and serves as a potent histone deacetylase (HDAC) inhibitor, making it one of the most pharmacologically complex medications in clinical use. The CTD database documents 34,261 chemical-gene interactions for valproic acid — the highest count of any medication in our analysis — with 29,821 disease associations and 14,880 protein targets confirmed via STITCH. This extraordinary molecular footprint explains why valproate depletes more nutrients through more mechanisms than virtually any other single drug.

Five nutrients decline during valproate therapy, each through a distinct biochemical pathway. Carnitine depletion is the most clinically urgent: valproic acid directly inhibits carnitine biosynthesis, reduces renal reabsorption via the SLC22A5/OCTN2 transporter (CTD confirms SLC22A5 demethylation), creates valproylcarnitine conjugates that are excreted in urine, and inhibits mitochondrial beta-oxidation through decreased expression of CPT1A, CPT1B, and CPT2. This four-pronged assault depletes carnitine stores in 40-100% of users in a dose-dependent manner. Folate depletion occurs because valproate's HDAC inhibition disrupts methylation broadly, while it also directly interferes with glutamate formyltransferase and one-carbon metabolism. Vitamin B12 levels decline as valproate's extensive methylation changes impact the methionine synthase reaction. Zinc depletion stems from valproate's interaction with zinc-dependent HDAC enzymes — since HDACs require zinc at their active sites and valproate chelates zinc as part of its mechanism, chronic treatment increases zinc turnover and excretion. Selenium stores fall as valproate-driven hepatic metabolism depletes glutathione, increasing demand for selenium-dependent antioxidant enzymes like glutathione peroxidase.

The clinical consequences of these combined depletions range from daily-quality-of-life impairments to life-threatening emergencies. Carnitine deficiency manifests as severe fatigue, muscle weakness, and — most dangerously — hepatotoxicity and hyperammonemia. Hyperammonemia from valproate can present as confusion, lethargy, and cognitive dulling that mimics bipolar episodes, leading clinicians to increase the dose of the very drug causing the problem. FAERS reports document fatal cases of valproate hepatotoxicity, particularly in children under 2 on polytherapy, where carnitine depletion is the primary contributing factor. Folate depletion carries an FDA Black Box Warning for pregnancy: valproate causes neural tube defects in 1-2% of exposed pregnancies (10-20 times baseline risk) and cognitive impairment with an 8-15 point IQ reduction. Hair loss — affecting 10-20% of users — results from combined zinc and selenium deficiency rather than a direct drug effect, making it partially reversible with supplementation. Weight gain (40-70% of users) involves multiple mechanisms: carnitine depletion impairs fat oxidation, zinc deficiency alters appetite regulation, and valproate directly affects insulin sensitivity. CTD data confirms CYP19A1 (aromatase) interactions, explaining why 8-12% of women develop PCOS-like symptoms including hyperandrogenism and menstrual irregularity.

Comprehensive monitoring for valproate patients must include nutrients beyond the standard liver function panels. Free and total carnitine plus acylcarnitine profiles establish baseline carnitine status and track depletion over time. Ammonia levels require immediate testing if any cognitive changes, confusion, or unexplained lethargy develop — valproate-induced hyperammonemia can occur even without elevated liver enzymes. L-carnitine supplementation at 1-3 grams daily for adults (10-20 mg/kg daily for children) is protective against hepatotoxicity and hyperammonemia without reducing anticonvulsant efficacy. [RBC folate](/biomarkers) and homocysteine monitoring is essential, with L-methylfolate at 1-5 mg daily (higher than standard due to multiple folate enzyme disruptions). Zinc at 25-50 mg daily and selenium at 100-200 mcg daily address the hair loss and antioxidant deficits. Women of reproductive age on valproate require regular pregnancy testing and reliable contraception, with proactive discussion of alternative mood stabilizers before conception planning. Liver function tests at baseline, 1 month, 3 months, then every 6-12 months complete the monitoring framework.